Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-10-11 08:55 am Sale | 2022-09-30 | 13G | Calidi Biotherapeutics, Inc. CLDI | DRIEHAUS CAPITAL MANAGEMENT LLC | 8,333 24.220% | -4,167 (-33.33%) | Filing History |
| 2022-07-11 10:28 am Sale | 2022-06-08 | 13G | Elevation Oncology, Inc. ELEV | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,044,244 4.490% | -458,524 (-30.51%) | Filing History |
| 2022-06-15 11:28 am Purchase | 2021-11-30 | 13G | The Real Good Food Company, Inc. RGF | DRIEHAUS CAPITAL MANAGEMENT LLC | 66,405 12.920% | 66,405 (New Position) | Filing History |
| 2022-06-13 1:50 pm Purchase | 2021-12-31 | 13G | MELI Kaszek Pioneer Corp MEKA | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,957,541 6.590% | 1,957,541 (New Position) | Filing History |
| 2022-06-10 09:02 am Sale | 2022-05-31 | 13G | Elevation Oncology, Inc. ELEV | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,502,768 6.460% | -479,695 (-24.20%) | Filing History |
| 2022-04-08 09:47 am Sale | 2022-03-31 | 13G | ChannelAdvisor Corporation ECOM | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,421,532 4.670% | -674,297 (-32.17%) | Filing History |
| 2022-02-14 09:42 am Sale | 2021-12-31 | 13G | Cytokinetics, Incorporated CYTK | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,327,112 2.770% | -712,144 (-23.43%) | Filing History |
| 2022-02-14 09:28 am Purchase | 2021-12-31 | 13G | Calidi Biotherapeutics, Inc. CLDI | DRIEHAUS CAPITAL MANAGEMENT LLC | 12,500 5.220% | 12,500 (New Position) | Filing History |
| 2022-02-14 09:24 am Purchase | 2021-12-31 | 13G | DICE Therapeutics, Inc. DICE | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,146,642 5.610% | 2,146,642 (New Position) | Filing History |
| 2022-02-14 09:19 am Purchase | 2021-12-31 | 13G | Elevation Oncology, Inc. ELEV | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,982,463 8.540% | 1,982,463 (New Position) | Filing History |
| 2022-02-14 09:14 am Purchase | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | DRIEHAUS CAPITAL MANAGEMENT LLC | 3,123,229 6.050% | 3,123,229 (New Position) | Filing History |
| 2022-01-10 11:09 am Purchase | 2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX | DRIEHAUS CAPITAL MANAGEMENT LLC | 4,793,638 10.090% | 4,793,638 (New Position) | Filing History |
| 2021-10-04 10:03 am Purchase | 2021-09-14 | 13G | ESSA Pharma Inc. EPIX | DRIEHAUS CAPITAL MANAGEMENT LLC | 346,146 2.300% | 83,976 (+32.03%) | Filing History |
| 2021-08-23 4:55 pm Sale | 2021-08-16 | 13G | ESSA Pharma Inc. EPIX | DRIEHAUS CAPITAL MANAGEMENT LLC | 0 0.000% | -1,048,524 (Position Closed) | Filing History |
| 2021-05-10 09:44 am Purchase | 2021-04-09 | 13G | ESSA Pharma Inc. EPIX | DRIEHAUS CAPITAL MANAGEMENT LLC | 262,170 11.430% | 262,170 (New Position) | Filing History |
| 2021-02-16 09:42 am Unchanged | 2020-12-31 | 13G | ESSA Pharma Inc. EPIX | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,048,524 5.030% | 0 (Unchanged) | Filing History |
| 2021-02-16 09:40 am Unchanged | 2020-12-31 | 13G | ChannelAdvisor Corporation ECOM | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,095,829 7.230% | 0 (Unchanged) | Filing History |
| 2021-02-16 09:22 am Purchase | 2020-12-31 | 13G | ChannelAdvisor Corporation ECOM | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,095,829 7.230% | 2,095,829 (New Position) | Filing History |
| 2021-02-16 09:15 am Purchase | 2020-12-31 | 13G | ESSA Pharma Inc. EPIX | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,048,524 5.030% | 1,048,524 (New Position) | Filing History |